drugset
drugset / Trial / NCT06111196

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

NCT06111196 ↗

Phase 1 Completed 59 enrolled Bio-Thera Solutions
RandomizedParallel-groupQuadruple-blindTreatment

Summary

to Compare the Pharmacokinetics and Safety of BAT3306 versus KEYTRUDA® Administered in Healthy Male Subjects

Timeline

Start
2023-11-05
Primary completion
2024-06-11
Completion
2024-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BAT3306 Monoclonal antibody 100 mg Intravenous
Comparator Pembrolizumab Monoclonal antibody 100 mg Intravenous

Indications

No indication recorded.